Highlights the need to distinguish MHS patients with secondary multiminicore lesions (potentially due to RYR1 mutations) from those with true multiminicore disease.
No takes yet. Share an insight, caveat, or question.
Clinicians should differentiate secondary multiminicore lesions in MHS from true congenital disease; case reports leave RYR1 causality open for confirmation.
Guis et al. (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: